-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan for patients living with acquired hypothalamic obesity -- Oct. 13, 2026 -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the commercial launch of

A spin-out focused on AI-enabled decoding of the deliverome Proprietary synthetic biology platform identifies conjugates that target RNA medicines beyond the liver, with initial focus on renovascular disease Round co-led by 4BIO Capital and IQ Capital, with participation from Verve Ventures, Harel Tech, Entree Capital, Kerna Ventures and Saras Capital Undecimal Bio (“Undecimal”), a platform biotechnology company advancing targeted delivery of siRNA therapeutics, today announced an oversubscribe

Oct. 13, 2026 -- Rona Therapeutics today announced it has granted Roche (SIX: RO, ROG; OTCQX: RHHBY) an exclusive worldwide license for Rona's investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company's proprietary extrahepatic delivery platform. ALK7, encoded by the ACVR1C gene, is predominantly expressed in adipose tissue and is a genetically validated target for obesity and metabolic diseases. Inhibition of ALK7 by directly targeting adipocytes has

Oct. 12, 2026 -- Xodus Medical, a leading developer and manufacturer of innovative surgical safety solutions, today announced that it has entered into an agreement to be acquired by STERIS, a global provider of products and services that support patient care with an emphasis on infection prevention. The acquisition represents a significant milestone in Xodus Medical's more than 30-year history, bringing together two organizations with a shared commitment to advancing patient safety, supporting

Oct. 12, 2026 -- Sharp Biomedical, a medical device company pioneering accessible, safe, and manual procedures for outpatient pain clinics, announced today the successful closing of its pre-seed funding round. The round was led by gener8tor 1889, a North Dakota venture capital fund, with participation from several physician angel investors. Dan Newman, Founder and CEO The new capital will fully fund the development and testing pathway necessary to bring Sharp Biomedical's first purpose-built too

Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences” or the “Company”)(SSE: 688321) announced that the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for CS43158 tablets, a new molecular entity for the treatment of acute myeloid leukemia (AML), discovered through the company’s AI-enabled Chemical Genomics Platform. CS43158 is a multikinase inhibitor with global patent protection, independently developed by Chipscr

Final independent safety review identifies no findings warranting study changes and recommends that AURORA continue as planned All patients have completed dosing in the global AURORA study evaluating the efficacy and safety of CAL101 in adults with IPF; topline results expected in Q1 2027 Calluna Pharma AS (Calluna), a clinical-stage biotechnology company pioneering first-in-class antibodies for inflammatory and fibrotic diseases, today announced completion of dosing in the Phase 2 AURORA study

Oct. 12, 2026 -- Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect against serious infectious diseases, today announced that interim data from the company's Phase 1/2a pediatric clinical trial of RSV vaccine candidate BLB201 will be presented as a late-breaking abstract during the International Society for Vaccines 2026 Annual Congress in Antwerp, Belgi

Bristol Myers Squibb said Monday that the asset at the centre of its $4.1-billion purchase of RayzeBio — an experimental radiopharmaceutical therapy (RPT) dubbed RYZ101 — hit the primary endpoint of a Phase III study for certain patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). The ACTION-1 trial enrolled patients with somatostatin receptor-positive GEP-NETs who have progressed following treatment with lutetium-177 (Lu177)-based therapy. Participants were randomised to rec

Collaboration expands access to Lunit's AI-powered pathology platform by combining it with Discovery Life Sciences' global biospecimen and specialty laboratory capabilities, enabling standardized tissue insights for biomarker research and drug development. Oct. 12, 2026 -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced a strategic collaboration with Discovery Life Sciences (Discovery), a global leader in biospecimens and specialty la